Cantor Fitzgerald Comments on Omeros FY2025 Earnings

Omeros Co. (NASDAQ:OMER) – Analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Omeros in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst O. Brayer anticipates that the biopharmaceutical company will post earnings of ($1.73) per share for the year. Cantor Fitzgerald has a “Neutral” rating on the stock. The consensus estimate for Omeros’ current full-year earnings is ($3.09) per share.

OMER has been the subject of a number of other research reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a report on Friday, January 17th. Rodman & Renshaw assumed coverage on shares of Omeros in a research report on Thursday, November 14th. They issued a “buy” rating and a $9.00 price target on the stock. StockNews.com raised shares of Omeros from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. RODMAN&RENSHAW upgraded Omeros to a “strong-buy” rating in a research note on Thursday, November 14th. Finally, D. Boral Capital reiterated a “buy” rating and set a $36.00 price target on shares of Omeros in a research report on Thursday, January 16th. Three analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Omeros has an average rating of “Moderate Buy” and an average price target of $22.50.

Omeros Trading Down 3.0 %

Shares of OMER opened at $9.01 on Wednesday. Omeros has a 52 week low of $2.61 and a 52 week high of $13.60. The firm has a market cap of $522.13 million, a price-to-earnings ratio of -3.90 and a beta of 2.01. The stock has a 50 day moving average of $9.65 and a 200-day moving average of $6.13.

Institutional Trading of Omeros

Several hedge funds have recently bought and sold shares of OMER. Barclays PLC increased its stake in shares of Omeros by 121.3% in the third quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company’s stock valued at $376,000 after purchasing an additional 51,873 shares during the period. State Street Corp boosted its position in shares of Omeros by 0.3% during the third quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock worth $4,867,000 after buying an additional 3,839 shares during the period. HighTower Advisors LLC increased its position in Omeros by 7.2% in the 3rd quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company’s stock valued at $235,000 after acquiring an additional 4,000 shares during the period. MML Investors Services LLC increased its position in Omeros by 19.2% in the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock valued at $74,000 after acquiring an additional 3,000 shares during the period. Finally, Wellington Management Group LLP bought a new stake in Omeros during the 3rd quarter valued at $305,000. 48.79% of the stock is currently owned by institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.